Radiotherapy & Oncology
Volume 86, Issue 3 , Pages 361-368 , March 2008

PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck

  • Christine Bayer

      Affiliations

    • Department of Radiation Oncology, Technical University of Munich, Munich, Germany
    • Corresponding Author InformationCorresponding author. Christine Bayer, Department of Radiation Oncology, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany.
    • ,
  • Daniela Schilling

      Affiliations

    • Department of Radiation Oncology, Technical University of Munich, Munich, Germany
    • ,
  • Joerg Hoetzel

      Affiliations

    • Department of Radiation Oncology, Technical University of Munich, Munich, Germany
    • ,
  • Hannes Peter Egermann

      Affiliations

    • Department of Radiation Oncology, Technical University of Munich, Munich, Germany
    • ,
  • Daniel Zips

      Affiliations

    • Department of Radiation Oncology, Carl Gustav Carus University of Technology, Dresden, Germany
    • ,
  • Ala Yaromina

      Affiliations

    • Department of Radiation Oncology, Carl Gustav Carus University of Technology, Dresden, Germany
    • ,
  • Anneke Geurts-Moespot

      Affiliations

    • Department of Chemical Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • ,
  • Lisa Deborah Sprague

      Affiliations

    • Institute of Molekulare Pathogenese, Friedrich-Loeffler-Institut, Bundesforschungsinstitut for Tiergesundheit, Jena, Germany
    • ,
  • Fred Sweep

      Affiliations

    • Department of Chemical Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • ,
  • Michael Baumann

      Affiliations

    • Department of Radiation Oncology, Carl Gustav Carus University of Technology, Dresden, Germany
    • ,
  • Michael Molls

      Affiliations

    • Department of Radiation Oncology, Technical University of Munich, Munich, Germany
    • ,
  • Markus Adam

      Affiliations

    • Radiotherapy Practice, Weilheim, Germany

Received 20 August 2007 ,Revised 9 November 2007 ,Accepted 9 November 2007.

References 

  1. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28:29–35
  2. Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood. 1999;94:4177–4185
  3. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843–845
  4. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist. 2004;9:10–17
  5. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1–22
  6. Young AM, Aronson DL, Finlayson JS. A urokinase-incubation method for predicting the stability of immune globulin. J Biol Stand. 1978;6:27–43
  7. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57:25–40
  8. Harbeck N, Thomssen C, Berger U, et al. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat. 1999;54:147–157
  9. Harbeck N, Alt U, Berger U, et al. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. Int J Biol Markers. 2000;15:79–83
  10. Harbeck N, Kates RE, Schmitt M, et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer. 2004;5:348–352
  11. Look MP, van Putten LJ, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116–128
  12. Chin D, Boyle GM, Williams RM, et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer. 2005;113:789–797
  13. Hundsdorfer B, Zeilhofer HF, Bock KP, et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity – clinical relevance and prognostic value. J Craniomaxillofac Surg. 2005;33:191–196
  14. Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck. Anticancer Res. 2000;20:3975–3981
  15. Reinmuth N, Parikh AA, Ahmad SA, et al. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech. 2003;60:199–207
  16. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol. 2000;18:2046–2052
  17. Manders P, Sweep FCGJ, Tjan-Heijnen VCG, et al. Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients. Clin Cancer Res. 2003;9:6363–6370
  18. Aebersold DM, Beer KT, Laissue J, et al. Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Oncol Biol Phys. 2000;48:17–25
  19. Manders P, Beex LVAM, Tjan-Heijnen VCG, Span PN, Sweep CGJ. Vascular endothelial growth factor levels do not predict efficacy of systemic adjuvant treatment as assessed in 1127 breast cancer patients. Int J Oncol. 2004;25:511–517
  20. Eppenberger U, Kueng W, Schlaeppi JM, et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol. 1998;16:3129–3136
  21. Meo S, Dittadi R, Peloso L, Gion M. The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer. Int J Biol Markers. 2004;19:282–288
  22. Yaromina A, Krause M, Thames H. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol. 2007;83:304–310
  23. Yaromina A, Zips D, Thames HD, et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol. 2006;81:122–129
  24. Yaromina A, Hoelscher T, Eicheler W, et al. Does hererogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. Radiother Oncol. 2005;76:206–212
  25. Grebenschikov N, Geurts-Moespot A, De Witte H, et al. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers. 1997;12:6–14
  26. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem. 1995;270:13333–13340
  27. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res. 1995;77:638–643
  28. Maity A, Pore N, Lee J, Solomon D, O’Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res. 2000;60:5879–5886
  29. Graham CH, Fitzpatrick TE, McCrae KR. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood. 1998;91:3300–3307
  30. Graham CH, Forsdike J, Fitzgerald CJ, Donald-Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer. 1999;80:617–623
  31. Weinmann M, Thews O, Schroeder T, Vaupel P. Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: role of oxygenation status and tumour size. Br J Cancer. 2002;86:1355–1361
  32. Hjortland GO, Lillehammer T, Somme S, et al. Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells. Exp Cell Res. 2004;294:130–139
  33. Brooks TD, Slomp J, Quax PH, et al. Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro. Clin Exp Metastasis. 2000;18:445–453
  34. Brooks TD, Wang SW, Brunner N, Charlton PA. XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro. Anticancer Drugs. 2004;15:37–44
  35. Devy L, Blacher S, Grignet-Debrus C, et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 2002;16:147–154
  36. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998;4:923–928
  37. Bajou K, Maillard C, Jost M, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene. 2004;23:6986–6990
  38. Mandriota SJ, Seghezzi G, Vassalli JD, et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem. 1995;270:9709–9716
  39. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun. 1991;181:902–906
  40. Berney CR, Yang JL, Fisher RJ, Russell PJ, Crowe PJ. Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. Anticancer Res. 1998;18:973–977
  41. Terada H, Urano T, Konno H. Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer. Eur Surg Res. 2005;37:166–172
  42. Offersen BV, Pfeiffer P, Andreasen P, Overgaard J. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer. 2007;56:43–50
  43. Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001;93:913–920
  44. Speleman L, Kerrebijn JDF, Look MP, et al. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Head Neck. 2007;29:341–350
  45. Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost. 2006;4:2710–2715
  46. Koong AC, Denko NC, Hudson KM, et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000;60:883–887
  47. Schilling D, Bayer C, Geurts-Moespot A, et al. Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines. BMC Cancer. 2007;7:143
  48. Sprague LD, Mengele K, Schilling D, et al. Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells. Oncology. 2006;71:282–291
  49. Eriksen JG, Horsman MR. Tumor hypoxia – a characteristic feature with a complex molecular background. Radiother Oncol. 2006;81:119–121
  50. Moeller BJ, Dreher MR, Rabbani ZN, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005;8:99–110
  51. Williams KJ, Telfer BA, Xenaki D, et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol. 2005;75:89–98
  52. Zhang X, Kon T, Wang H, et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res. 2004;64:8139–8142

PII: S0167-8140(07)00568-3

doi: 10.1016/j.radonc.2007.11.011

Radiotherapy & Oncology
Volume 86, Issue 3 , Pages 361-368 , March 2008

Article Tools

* Image Usage & Resolution